Johnson & Johnson Pharmaceutical Research and Development L. L. C., 3210 Merryfield Row, San Diego, CA 92121, USA. wchai@prdus.jnj.com
Abstract:
Continued exploration of the SAR around the lead imidazopyridine histamine H(3) antagonist 1 has led to the discovery of several related series of heterocyclic histamine H(3) antagonists. The synthesis and SAR of indolizine, indole and pyrazolopyridine based compounds are now described.